Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalTimes Interest Earned

MoonLake Immunotherapeutics (MLTX) Invested Capital (2020 - 2026)

MoonLake Immunotherapeutics' Invested Capital history spans 7 years, with the latest figure at $353.0 million for Q1 2026.

  • Quarterly Invested Capital fell 27.3% to $353.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $353.0 million through Mar 2026, down 27.3% year-over-year, with the annual reading at $378.6 million for FY2025, 15.27% down from the prior year.
  • Invested Capital came in at $353.0 million for Q1 2026, down from $378.6 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $552.4 million in Q1 2024 to a low of -$25.3 million in Q1 2022.
  • The 5-year median for Invested Capital is $431.3 million (2025), against an average of $342.2 million.
  • The largest YoY upside for Invested Capital was 11310.99% in 2022 against a maximum downside of 10205.8% in 2022.
  • MoonLake Immunotherapeutics' Invested Capital stood at $68.8 million in 2022, then soared by 646.71% to $513.5 million in 2023, then decreased by 12.98% to $446.8 million in 2024, then dropped by 15.27% to $378.6 million in 2025, then fell by 6.75% to $353.0 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Invested Capital are $353.0 million (Q1 2026), $378.6 million (Q4 2025), and $362.6 million (Q3 2025).